| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Department of Surgery, Ullevål University Hospital, Oslo, Norway; Departments of 2 Pathology, 3 Surgery, and 4 Oncology, The Norwegian Radium Hospital, Oslo, Norway; and 5 Department of Surgery, Bærum Hospital, Bærum, Norway
ABSTRACT
Purpose: The aim of the study was to explore the value of analyzing bone marrow (BM) for the presence of isolated tumor cell(s) (ITCs) in disease-free breast cancer patients 3 years after diagnosis.
Experimental Design: ITCs in BM at operation was found to be an independent prognostic factor in 817 breast cancer patients. Among these, 356 disease-free patients were analyzed with a second BM after 3 years follow-up (median 40 months, SD 3 months, range 29–52). ITC was detected by immunocytochemistry with anticytokeratine antibodies (AE1/AE3).
Results: The population consisted of 70% T1 and 72% node-negative patients. ITC in BM was detected in 15%. At a median of 25 months since the second BM aspiration (66 months since diagnosis), 32 patients had developed relapse, 12 local and 20 systemic. Of the patients with ITC in BM, 21% relapsed compared with 7% of the ITC-negative patients (P < 0.001). Ten patients died of breast cancer. Survival analyses showed that ITC in BM predicted reduced distant disease-free survival (DDFS) and breast cancer specific survival (BCSS; P < 0.001, log-rank test). Uni-and multivariate analyses of the prognostic value of N, T, estrogen receptor/progesterone receptor, and BM status, histological grade, vascular invasion, p53-, c-erb-B2-, and cathepsin D expression were performed. BM status was the only independent prognostic factor for both DDFS and BCSS, whereas c-erbB-2 and N status were independent for BCSS and vascular invasion and T status for DDFS.
Conclusions: ITC in BM 3 years after diagnosis in disease-free breast cancer patients is an independent prognostic factor. Detection of residual disease by BM analysis at follow-up may unravel insufficient adjuvant treatment. The clinical implications should be further explored.
This article has been cited by other articles:
|
|
 |
|
  F.-C. Bidard, A. Vincent-Salomon, S. Gomme, C. Nos, Y. de Rycke, J. P. Thiery, B. Sigal-Zafrani, L. Mignot, X. Sastre-Garau, J.-Y. Pierga, et al. Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse Clin. Cancer Res., June 1, 2008; 14(11): 3306 - 3311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Vincent-Salomon, F C Bidard, and J Y Pierga Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues J. Clin. Pathol., May 1, 2008; 61(5): 570 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-C. Bidard, A. Vincent-Salomon, B. Sigal-Zafrani, V. Dieras, C. Mathiot, L. Mignot, J.-P. Thiery, X. Sastre-Garau, and J.-Y. Pierga Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells Ann. Onc., March 1, 2008; 19(3): 496 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Xenidis, V. Markos, S. Apostolaki, M. Perraki, A. Pallis, G. Sfakiotaki, D. Papadatos-Pastos, L. Kalmanti, M. Kafousi, E. Stathopoulos, et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer Ann. Onc., October 1, 2007; 18(10): 1623 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakagawa, S. R. Martinez, Y. Goto, K. Koyanagi, M. Kitago, T. Shingai, D. A. Elashoff, X. Ye, F. R. Singer, A. E. Giuliano, et al. Detection of Circulating Tumor Cells in Early-Stage Breast Cancer Metastasis to Axillary Lymph Nodes Clin. Cancer Res., July 15, 2007; 13(14): 4105 - 4110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bandyopadhyay, J. K. Agyin, L. Wang, Y. Tang, X. Lei, B. M. Story, J. E. Cornell, B. H. Pollock, G. R. Mundy, and L.-Z. Sun Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-{beta} Type I Receptor Kinase Inhibitor. Cancer Res., July 1, 2006; 66(13): 6714 - 6721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pantel and U. Woelfle Circulating Tumor Cells as an Indicator of Invasion Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 116 - 119. [Full Text] [PDF]
|
|
|
|
|
|
P. Wulfing, J. Borchard, H. Buerger, S. Heidl, K. S. Zanker, L. Kiesel, and B. Brandt HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients. Clin. Cancer Res., March 15, 2006; 12(6): 1715 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 Ann. Onc., October 1, 2005; 16(10): 1569 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Krag, R. Kusminsky, E. Manna, A. Ambaye, D. L. Weaver, S. P. Harlow, M. Covelli, M. A. Stanley, L. McCahill, F. Ittleman, et al. The Detection of Isolated Tumor Cells in Bone Marrow Comparing Bright-Field Immunocytochemistry and Multicolor Immunofluorescence Ann. Surg. Oncol., September 1, 2005; 12(9): 753 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Janni, B. Rack, K. Lindemann, and N. Harbeck Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time? Oncologist, August 1, 2005; 10(7): 480 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pantel Bone marrow: Homing organ for dormant micrometastatic cancer cells AACR Meeting Abstracts, April 1, 2005; 2005(1): 1477 - 1478. [Abstract]
|
|
|
|
 |
|
 S. Braun and B. Naume Circulating and Disseminated Tumor Cells J. Clin. Oncol., March 10, 2005; 23(8): 1623 - 1626. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
